Real Life Remote Monitoring of Mild, Moderate and Severe Infectious Complications in IBD by Patient Reported Assessment

Ulcerative Colitis Clinical Trial

Official title:

Validation and Implementation of a Digital Patient Reported Remote Monitoring Tool to Systematically Monitor Mild, Moderate and Severe Infectious Complications in IBD Patients in Routine Care

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04151420
• Other study ID #: MEC 2019-1115
• Status: Completed
• Start date: June 15, 2020
• Est. completion date: February 1, 2022

Study information

• Verified date: June 2022
• Source: Maastricht University Medical Center
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Inflammatory bowel disease (IBD) is a chronic relapsing immune mediated inflammatory disease (IMID) of the gastrointestinal tract. Like all IMIDs (e.g. rheumatoid arthritis, psoriasis) a complex interaction between a genetically altered immune response, the gut microbiota and environmental factors is causing the disease. Systemic suppression of the immune response with corticosteroids, immunomodulatory, biologicals and combination therapies increases the risk of opportunistic infections in IBD patients.

Data on mild and moderate infections in medically treated IBD patients is scarce, mainly since infections treated by the general practitioner or in an outpatient setting are not systematically registered in real life. To help gastroenterologists with clinical decision making, real world data with long term follow-up concerning the risk for infectious complications, is warranted.

Several observations underline the importance of real world data on mild and moderate infections in medically treated IBD patients. Mild and moderate infections mostly have a benign course, but they take longer to clear and have a large impact on (work)disability and quality of life in IBD patients. Recurrent infections influences peoples willingness to use a drug and negatively effects adherence. Furthermore, recurring mild and moderate infections might prognosticate serious infections, and systematic assessment of all infections could be used to timely adjust treatment regimens and prevent serious infections.

The investigators of this study previously developed a questionnaire on self-reported infections according to the FDA guideline for patient-reported outcome measures (PROM) by interviewing 36 patients with IBD and through input of expert meetings with gastroenterologists, IBD specialists, rheumatologists, immunologists and IBD-nurses. This questionnaire has already been implemented in myIBDcoach, a validated telemedicine system implemented in routine care for over 4000 patients with IBD in the Netherlands. Assesment of reliability and validity are the last steps in validation of this remote monitoring tool.

In the current study the investigators aim to:

1. Assess the reliability, construct validity and criterion validity of a remote monitoring tool (questionnaire) for infections as last step in the validation

2. Assess the relative risk of all infections (mild, moderate and severe) in a real-life population for IBD patients on different maintenance treatments

3. Identify the predictors and risk factors of mild and moderate infections.

4. Assess the relation between patient reported infections and the risk for serious infectious complications

Recruitment information / eligibility

• Status: Completed
• Enrollment: 584
• Est. completion date: February 1, 2022
• Est. primary completion date: September 21, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 70 Years

Eligibility

Inclusion Criteria:

• Age = 18 years and diagnosed with IBD

• Included in eHealth clinical care-pathway using myIBDcoach

Exclusion Criteria:

• Patients with insufficient knowledge of the Dutch language

• Patients not able to provide written informed consent

Related Conditions & MeSH terms

• Crohn Disease
• Digestive System Disease
• Digestive System Diseases
• Gastrointestinal Diseases
• IBD
• Inflammatory Bowel Diseases
• Patient Reported Outcome Measures
• Ulcerative Colitis

Intervention

Other:
• Remote monitoring tool (infections questionnaire) validation
There will be no treatment intervention in the current study (no drugs will be used). Instead, patients are enrolled in a routine care eHealth care-pathway with myIBDcoach. MyIBDcoach (MijnIBDcoach, Dutch, Sananet Care B.V., Sittard, The Netherlands, https://www.mijnibdcoach.nl) is a web-based platform for home-monitoring and patient- provider communication in patients with IBD. Patients already using the myIBDcoach will be informed on this study. Patients will be asked to continue routine care including monitoring of PROs through the myIBDcoach. When a patient completes the infections disease questionnaire for the first time, this will be regarded as the starting point (T=0) for this patient. Patients will complete the questionnaire every three months after the starting point as part of their routine follow-up. Results from these questionnaires will be stored electronically and will be analyzed alongside medical records of GP's and drug delivery data from pharmacies.

Locations

Country	Name	City	State
Netherlands	Maastricht University Medical Centrer	Maastricht
Netherlands	Zuyderland Medical Centre	Sittard

Sponsors (2)

Lead Sponsor	Collaborator
Maastricht University Medical Center	Takeda

Country where clinical trial is conducted

Netherlands, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Remote monitoring tool validation	Assess the reliability, construct validity and criterion validity of a PRO for infections in IBD patients as last step in the validation.	24 months
Secondary	Relative risk of all infections	Assess the relative risk of all infections (mild, moderate and severe) in a real life population for IBD patients on different maintenance treatments	12 months
Secondary	Relation between mild/moderate and serious infectious complications	Assess the relation between patient reported infections and the risk for serious infectious complications	6-12 months